Swiss specialty pharmaceutical company, Santhera Pharmaceuticals, has received a negative opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for its revised marketing authorisation application for Raxone in DMD more

15 Sep 2017 12:07 News

Santhera Pharmaceuticals has announced that the MHRA has granted a positive scientific opinion through the Early Access to Medicines Scheme (EAMS) to Raxone (idebenone) for patients with respiratory function decline not taking glucocorticoids in DMD more

22 Jun 2017 12:40 News